

---

## MICHELE ANTONELLI APPOINTED PRESIDENT OF STALLERGENES SAS AND EXECUTIVE VICE PRESIDENT, HEAD OF EUROPE & REST OF WORLD

**DATE: February 10, 2016**

London (United Kingdom) - Stallergenes Greer plc (the “Company”) (Euronext Paris: STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, today announced the appointment of Michele Antonelli as President of Stallergenes SAS and Executive Vice President, Head of Europe & Rest of World (excluding the Americas). He is succeeding Christian Chavy in these positions.

Michele has more than 20 years of international experience in the biopharmaceutical industry with extensive expertise in both manufacturing and commercial. He joined Stallergenes SAS in November 2015 as Executive Vice President, Head of International Operations. Michele previously worked at UCB where he held roles of various responsibility and scope, most recently serving as Executive Vice President and Head of Immunology Europe, overseeing the region’s commercial, medical, and market access activities. Prior to joining UCB, Michele spent 16 years at Merck Serono, ultimately serving as Senior Vice President and Global Head of Biotech Manufacturing and Process Development.

Fereydoun Firouz, Chairman and Chief Executive Officer of Stallergenes Greer, said:

*“Since joining us late last year, Michele has made an immediate, positive impact by assuming leadership for and overseeing the resolution of the operational disruptions caused by the implementation of our new IT system at our plant in Antony, France. Michele’s primary focus will be to deliver the value proposition of our state-of-the-art medicines to key Allergy Immunotherapy markets. He will also play a pivotal role in helping build our commercial organizational structure under the global Stallergenes Greer umbrella, ensure our commitment to remaining customer-centric, and help strengthen our culture dedicated to innovation and excellence in execution.”*

*“I would like to thank Christian for his contribution in bringing Stallergenes and Greer together – creating a new global allergy company – and helping expand access to our therapies for patients suffering with allergies in Europe and beyond. I wish him the best in his future endeavours.”*

## ABOUT STALLERGENES GREER PLC

Headquartered in London (UK), Stallergenes Greer plc is a global healthcare company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France).

### Trading information:

Name: Stallergenes Greer

ISIN: GB00BZ21RF93 1 - Ticker: STAGR

ICB classification: 4577

Market: Euronext Paris regulated market

Additional information is available at <http://www.stallergenesgreer.com>

*This document (including information incorporated by reference in this document), oral statements made and other information published by the company contain statements that are or may be forward-looking with respect to the financial condition and/or results of operations and businesses of the Company. These statements can be identified by the use of forward-looking terminology such as "believe", "expects", "project", "estimated", "forecast", "should", "plan", "may" or the negative of any of these, or other variations thereof, or comparable terminology indicating expectations or beliefs concerning future events. These forward-looking statements include risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, and changes in competitive factors. These and other factors are more fully described in our prospectus filed with the French Autorité des marchés financiers on September 3, 2015. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Save as required by applicable law, neither the Company nor any other person assumes any obligation to update these forward-looking statements or to notify any person of any such update.*

### Contacts:

#### Investor and analyst relations

Peter Bühler  
 Chief Financial Officer  
 Tel: +33 1 55 59 23 22  
 Email: [investorrelations@aresallergyco.com](mailto:investorrelations@aresallergyco.com)

#### Media relations

Lise Lemonnier  
 Head of Global Communications  
 Tel: + 33 1 55 59 20 96  
 Email: [llemonnier@stallergenes.com](mailto:llemonnier@stallergenes.com)

#### Investor relations agency

FTI Consulting  
 Arnaud de Cheffontaines  
 Tel: +33 1 47 03 69 48  
 Email:  
[arnaud.decheffontaines@fticonsulting.com](mailto:arnaud.decheffontaines@fticonsulting.com)